{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Prostate", "query": { "condition": "Malignant Neoplasm of Prostate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 341, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Prostate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T02:07:53.195Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00120939", "title": "Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Ovarian Neoplasms", "Prostatic Neoplasms", "Lung Neoplasms", "Gastrointestinal Neoplasms" ], "interventions": [ { "name": "Motexafin Gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharmacyclics LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2009-04-03", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00120939" }, { "nct_id": "NCT02565901", "title": "Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer AJCC v7", "Metastatic Malignant Neoplasm in the Bone" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2016-02-29", "completion_date": "2020-06-16", "has_results": true, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02565901" }, { "nct_id": "NCT03388346", "title": "68Ga PSMA in Preprostatectomy Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer", "Prostatic Neoplasm", "Prostatic Neoplasms, Castration-Resistant", "Prostatic Neoplasm of Uncertain Behavior" ], "interventions": [ { "name": "Ga-68 PSMA-HBED-CC PET", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Graham PhD, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 22, "start_date": "2018-02-16", "completion_date": "2021-07-22", "has_results": true, "last_update_posted_date": "2024-02-15", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03388346" }, { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Advanced Malignant Neoplasm", "Metastatic Cancer", "Metastatic Solid Tumor", "Lung Cancer", "Ovarian Cancer", "Endometrial Cancer", "Prostate Cancer", "Colorectal Cancer", "Breast Cancer", "Other Cancer", "Locally Advanced", "Head and Neck Cancer", "Gall Bladder Cancer", "Small Cell Lung Cancer", "Small Cell Lung Cancer ( SCLC )", "Small Cell Lung Carcinoma", "NSCLC", "NSCLC (Non-small Cell Lung Cancer)", "SCLC", "Non-Small Cell Lung Carcinoma", "Triple Negative Breast Cancer", "TNBC", "HER2+ Breast Cancer", "Non-Small Cell Lung Cancer", "ER/PR Positive Breast Cancer", "HER2- Breast Cancer", "HER2-positive Breast Cancer", "HER2-negative Breast Cancer", "ER/PR(+), Her2(-) Breast Cancer" ], "interventions": [ { "name": "rezatapopt", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PMV Pharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 300, "start_date": "2020-10-29", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 32, "location_summary": "Irvine, California • La Jolla, California • Los Angeles, California + 25 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585750" }, { "nct_id": "NCT05252390", "title": "NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Ovarian Cancer", "Ovary Cancer", "Cancer of Ovary", "Cancer of the Ovary", "Ovary Neoplasm", "Pancreatic Cancer", "Pancreas Cancer", "Cancer of Pancreas", "Cancer of the Pancreas", "Pancreas Neoplasm", "Prostate Cancer", "Prostatic Cancer", "Cancer of Prostate", "Cancer of the Prostate", "Prostate Neoplasm", "Castrate Resistant Prostate Cancer", "Castration Resistant Prostatic Cancer", "Castration Resistant Prostatic Neoplasms", "Triple-negative Breast Cancer", "Triple Negative Breast Cancer", "Triple Negative Breast Neoplasms", "Breast Cancer", "Breast Carcinoma", "Cancer of Breast", "Cancer of the Breast", "Breast Tumor" ], "interventions": [ { "name": "NUV-868", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2022-03-29", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05252390" }, { "nct_id": "NCT03649841", "title": "Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Sensitive Prostate Carcinoma", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Prostate Small Cell Neuroendocrine Carcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 10, "start_date": "2020-06-29", "completion_date": "2023-02-01", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03649841" }, { "nct_id": "NCT03424850", "title": "Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer", "Prostate Neoplasm" ], "interventions": [ { "name": "HDR brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2018-02-27", "completion_date": "2030-02-28", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03424850" }, { "nct_id": "NCT02065323", "title": "A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Standard ADT", "type": "DRUG" }, { "name": "Dovitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oscar Goodman, Jr.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2015-01-19", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02065323" }, { "nct_id": "NCT04604158", "title": "Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer", "Cancer Metastatic", "Neoplasms", "Breast Cancer", "Lung Cancer", "Glioblastoma", "Prostate Cancer", "Gynecologic Cancer", "Colorectal Cancer", "Sarcoma", "Kidney Cancer", "Bladder Cancer", "Lymphoma", "Leukemia", "Head and Neck Cancer", "Pancreas Cancer", "Multiple Myeloma", "Anxiety", "Social Isolation", "Stress", "Loneliness", "Melanoma", "Uterine Cancer" ], "interventions": [ { "name": "Elly Mobile Phone Application", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Gillian Gresham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2020-12-02", "completion_date": "2024-05-17", "has_results": false, "last_update_posted_date": "2024-05-21", "last_synced_at": "2026-06-26T02:07:53.195Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04604158" } ] }